Obviousness

Under 35 U.S.C. § 103, a patent claim is obvious if "the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains." The effective filing date for US patent 11872029B1 is November 4, 2005.

The patent itself describes the existing state of the art in its "BACKGROUND OF THE INVENTION" section, highlighting the problems that the claimed invention seeks to solve. These descriptions serve as the relevant prior art for this analysis.

Prior Art References (as described in US11872029B1):

1. Physiological Sleep Disorder Diagnosis: All-night polysomnography (PPSG) was known for evaluating sleep architecture and obtaining the respiratory disturbance index to diagnose sleep apnea. While objective, these methods required all-day stays at clinics and were not well-suited for gauging the effects of therapeutic intervention. PPSG inherently involves monitoring various physiological signals, including brain waves (EEG), cardiac activity (ECG), respiratory effort, and oxygen saturation.
2. Sleep Apnea Treatment via CPAP: The application of continuous positive gas pressure (CPAP) was the most common method of treating sleep apnea.
3. Basic Adjustable CPAP Devices: "More advanced, but still very basic devices" for CPAP existed that adjusted continuous positive gas pressure using sensors built into the device that measured gas flow. However, these devices were deemed "expensive and largely ineffective" and, crucially, none of the devices on the market could adjust treatment based on a patient's current physiological state, current symptoms, predict the onset of symptoms, or adjust based on physiological signals such as EEG, EKG, or EMG.

Claimed Invention (from "SUMMARY OF THE INVENTION" of US11872029B1):

The invention generally describes a sleep disorder treatment system comprising a device for diagnosing and creating an output of a level of severity of a subject's sleeping disorder (or symptoms), and a treatment device (e.g., a CPAP device) that can be adjusted using this output. Various embodiments specify the types of sensors for diagnosis, including EEG electrodes, ECG electrodes, blood gas sensors, and pulse oximeter sensors, and emphasize automatic and/or predictive adjustment.

Obviousness Analysis and Motivation to Combine:

A person having ordinary skill in the art (POSA) in sleep medicine and medical device engineering, by November 4, 2005, would have been motivated to combine elements of known polysomnography (PPSG) diagnostic methods with continuous positive airway pressure (CPAP) treatment devices to overcome the acknowledged shortcomings of existing "basic adjustable" CPAP devices.

Combination: PPSG for comprehensive physiological monitoring + CPAP for treatment + Feedback Control System.

Motivation for Combination:
The patent explicitly identifies the problem: existing adjustable CPAP devices were "largely ineffective" because they relied solely on gas flow measurements and lacked the ability to adjust treatment based on a patient's broader "current physiological state," "current symptoms," or "physiological signals" like EEG, EKG, or EMG, nor could they "predict the onset of symptoms."

A POSA, aware of the comprehensive diagnostic capabilities of PPSG, would recognize that PPSG already gathered precisely the "physiological signals" that were missing from the feedback loop of the ineffective basic adjustable CPAP devices. PPSG utilized a range of sensors to capture:

• Brain wave signals (EEG): Essential for evaluating sleep architecture and detecting awakenings associated with apnea events.
• Cardiac signals (ECG/EKG): Used to detect cardiac abnormalities linked to respiratory-related sleep disorders.
• Respiratory effort: Measured by various means, including esophageal pressure and diaphragmatic EMG, to distinguish types of apnea.
• Oxygenation and Ventilation: Measured by pulse oximetry, transcutaneous oxygen/carbon dioxide monitoring, and expired carbon dioxide monitoring, directly indicating the impact of apnea on blood gas levels.

Given the goal of improving CPAP efficacy, it would have been obvious for a POSA to:

1. Integrate Diagnostic Sensing with Treatment: Take the physiological sensors (or a subset thereof) commonly used in PPSG (e.g., EEG, ECG, blood gas, pulse oximeter, respiratory effort sensors) and incorporate them into a system designed to work with a CPAP device. The motivation is to provide more comprehensive, real-time data about the patient's sleep state and symptoms than just airflow, which was the limitation of prior adjustable CPAP.

2. Implement Feedback Control: Apply known control system principles (closed-loop or open-loop) to use the output from these physiological sensors to automatically adjust the CPAP device (e.g., airflow rate or pressure). The patent explicitly mentions that its invention provides "a closed loop system or partly closed loop system or method, which automatically adjusts a treatment device based on analysis of a subject's sleeping disorder or symptoms," indicating this as a desired improvement over the prior art.

3. Achieve Predictive Treatment: While the patent states prior art did not predict symptom onset, it also describes various signal processing techniques (e.g., power spectrum analysis, ARMAX models, Short-Time Fourier Transforms, time-frequency transforms) for identifying "characteristic shifts" in physiological signals that indicate "imminent flow separation" or "onset of various critical symptoms." These signal processing techniques were known in the art prior to 2005. A POSA, motivated to provide anticipatory treatment, would find it obvious to apply these known analytical tools to the readily available physiological data (from PPSG-like sensors) to predict symptom onset and proactively adjust treatment.

Conclusion:

The core of the claimed invention in US11872029B1 lies in combining known diagnostic physiological monitoring (as exemplified by PPSG) with known CPAP therapy, and then employing known feedback control principles and signal processing techniques to automatically and/or predictively adjust the CPAP device based on the comprehensive physiological data. This combination would have been obvious to a POSA, driven by the clear motivation to overcome the stated limitations of existing "largely ineffective" adjustable CPAP devices that failed to utilize a patient's true physiological state and symptoms for responsive treatment. The patent's own background section clearly articulates the problems that such a combination would solve, thereby providing the necessary motivation for a POSA.